Premium
Genetic polymorphism of CCR2‐64I increased the susceptibility of hepatocellular carcinoma
Author(s) -
Yeh ChaoBin,
Tsai HsiuTing,
Chen YiChen,
Kuo WuHsien,
Chen TzyYen,
Hsieh YiHsien,
Chou MingChih,
Yang ShunFa
Publication year - 2010
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.21623
Subject(s) - ccr2 , hepatocellular carcinoma , medicine , genetic predisposition , gastroenterology , pathological , single nucleotide polymorphism , gene , oncology , chemokine , chemokine receptor , immunology , genotype , receptor , biology , disease , genetics
Background and Objectives The purpose of this study was to investigate genetic impact of monocyte chemoattractant protein‐1 (MCP‐1) and its receptor chemokine receptor‐2 (CCR2) gene polymorphisms on the susceptibility and clinicopathological characteristics of hepatocellular carcinoma (HCC). Methods A total of 446 subjects, including 344 healthy controls and 102 patients with HCC, were recruited in this study and subjected to PCR‐RFLP to estimate the impact of these two polymorphic variants on HCC. Results No relationship between MCP‐1 −2518G/A gene polymorphism and HCC risk was found among our recruited HCC patients and healthy controls. However, there was a significantly increased risk (AOR = 1.91; 95% CI = 1.11–3.29) of having HCC among subjects with GA heterozygotes of CCR2 V64I after adjusting for other confoundings. There was no synergistic effect between gene polymorphism and environmental risk factors, including tobacco and alcohol consumptions, as well as clinicopathological parameters of HCC for MCP‐1 −2518G/A and CCR2 V64I genes, respectively. Conclusions CCR2‐64I gene polymorphism is an important factor for the susceptibility of HCC but it might not influence the clinical pathological progression of HCC, and the contribution of CCR2‐64I gene polymorphism on the susceptibility of HCC could be not through the affection of liver injury‐related clinical pathological characteristics. J. Surg. Oncol. 2010;102:264–270. © 2010 Wiley‐Liss, Inc.